EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current Evidence on Safety, Efficacy and Efficiency of Sublingual Vaccine Uromune® in Prevention of Recurrent Urinary Tract Infections: A Literature Review

José Emilio Hernández-Sánchez, María Fernanda Lorenzo-Gómez, Carmen González-Enguita iD

Pathogens · 30.12.2025 · 15 (1) · 42

DOI: 10.3390/pathogens15010042 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pathogens, online erschienen am 30.12.2025. Verfasst von José Emilio Hernández-Sánchez und 2 weiteren Autor:innen. Beteiligte Einrichtung: General University Hospital of Villalba, 28400 Madrid, Spain. Hauptthemen laut MEDLINE: Urinary Tract Infections, Bacterial Vaccines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Urological Renal Multidisciplinary Research Group.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recurrent urinary tract infections (rUTIs) are a prevalent public health problem in women, with significant clinical, psychological, and economic consequences. Standard antibiotic prophylaxis, while effective, is limited in the medium term due to the risk of bacterial resistance and potential side effects. This narrative review summarizes the current evidence on the efficacy, safety, and economic impact of Uromune®—a sublingual bacterial vaccine—as a preventive strategy for rUTIs. A literature search was conducted, focusing on systematic reviews and meta-analyses that evaluated Uromune® in women and in other specific at-risk populations. Available data show that Uromune® reduces the frequency of UTI episodes, prolongs recurrence-free intervals, and decreases overall antibiotic use. The vaccine has a favorable safety profile, with predominantly mild adverse effects and a low discontinuation rate. Furthermore, its use has been associated with improved quality of life and a marked reduction in direct and indirect healthcare costs. These findings support Uromune® as an effective, safe, and potentially cost-effective alternative to conventional antibiotic prophylaxis in the current context of increasing antimicrobial resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Tract InfectionsBacterial VaccinesHumansAdministration, SublingualFemaleTreatment OutcomeCost-Benefit AnalysisRecurrence

Stichwörter der Autor:innen

UTIantimicrobial resistancecost-effectivenessimmunoprophylaxispublic healthsublingual vaccine

Substanzen

Bacterial Vaccines

Autor:innen und Institutionen

  • General University Hospital of Villalba, 28400 Madrid, Spain.
  • University Hospital of Salamanca, 37007 Salamanca, Spain.
  • Fundación Jiménez Díaz University Hospital, 28040 Madrid, Spain.

ORCID-Profile: Carmen González-Enguita

Förderung

  • Urological Renal Multidisciplinary Research Group

Zitieren

APA

Hernández-Sánchez, J. E., Lorenzo-Gómez, M. F., & González-Enguita, C. (2025). Current Evidence on Safety, Efficacy and Efficiency of Sublingual Vaccine Uromune® in Prevention of Recurrent Urinary Tract Infections: A Literature Review. Pathogens, 15(1), 42. https://doi.org/10.3390/pathogens15010042

Vancouver

Hernández-Sánchez JE, Lorenzo-Gómez MF, González-Enguita C. Current Evidence on Safety, Efficacy and Efficiency of Sublingual Vaccine Uromune® in Prevention of Recurrent Urinary Tract Infections: A Literature Review. Pathogens. 2025;15(1):42. doi:10.3390/pathogens15010042

BibTeX
@article{HernndezSnchez2025,
  author = {Hernández-Sánchez, José Emilio and Lorenzo-Gómez, María Fernanda and González-Enguita, Carmen},
  title = {Current Evidence on Safety, Efficacy and Efficiency of Sublingual Vaccine Uromune® in Prevention of Recurrent Urinary Tract Infections: A Literature Review},
  journal = {Pathogens},
  year = {2025},
  volume = {15},
  number = {1},
  pages = {42},
  doi = {10.3390/pathogens15010042}
}
Kostenlos starten →